Unity Biotechnology stock hits 52-week low at $0.66

Published 29/05/2025, 17:22
Unity Biotechnology stock hits 52-week low at $0.66

Unity Biotechnology Inc . (NASDAQ:UBX) shares have tumbled to a 52-week low, touching down at $0.66. With a current market capitalization of just $11.5 million, InvestingPro analysis suggests the stock is currently undervalued. This latest price level reflects a significant downturn for the biotech firm, which specializes in developing therapeutics to slow, halt, or reverse diseases of aging. Over the past year, Unity Biotechnology’s stock has witnessed a precipitous decline, with a 1-year change showing a staggering -57.05% drop. Despite the challenging market conditions, analyst targets range from $1 to $6 per share, suggesting potential upside. InvestingPro has identified 10 additional investment signals for UBX, available to subscribers. Investors are closely monitoring the company’s progress and potential catalysts that might reverse the downward trend, as the stock grapples with market pressures and investor sentiment. The company maintains a "Fair" overall financial health score according to InvestingPro metrics, with the next earnings report expected on July 22, 2025.

In other recent news, Unity Biotechnology Inc. has faced several updates affecting its stock and strategic direction. The company reported the complete 36-week results of its Phase 2b ASPIRE trial for UBX1325, which showed comparable vision gains to aflibercept in treating diabetic macular edema (DME). Despite not meeting the primary endpoint at weeks 20 and 24, UBX1325 demonstrated non-inferiority at nine out of ten time points over 36 weeks. Analysts from H.C. Wainwright and Mizuho (NYSE:MFG) Securities have downgraded Unity’s stock rating, with H.C. Wainwright setting a price target at $4.00 and Mizuho reducing it to $1.00. Mizuho’s decision reflects a more cautious outlook, while H.C. Wainwright maintains a Buy rating, citing potential for UBX1325. Unity is exploring strategic alternatives, including potential partnerships to further develop UBX1325. The company has also announced leadership changes and a revised operating plan to reduce operational costs. These developments indicate Unity’s focus on securing a strategic partner to advance its therapeutic candidate amid recent challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.